drugset / Trial / NCT06706895

A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer

NCT06706895

Phase 2 Not yet recruiting 21 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open, phase II clinical trial aimed at evaluating the anti-tumor efficacy and safety of paclitaxel polymeric micelles for injection combined with furquintinib as second-line treatment for advanced gastric cancer.

Timeline

Start
2024-12-01
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 4 mg Oral
Subject Paclitaxel Small molecule 120 mg/m2 Intravenous

Indications